David R. Brennan
Known title: DirectorCIK: 0001609305
David R. Brennan's purchase track record
David R. Brennan has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/1/2021 | INSM | $302K | -27.0% | -27.7% | -9.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INSM | ▼ Sell | Open Market | 25,000 | $3.1M | 9/9/2026 | View on chart |
| INSM | ▲ Buy | Grant | 3,305 | — | 5/13/2026 | View on chart |
| INSM | ▼ Sell | Gift | 6,000 | $0 | 2/23/2026 | View on chart |
| INSM | ▼ Sell | Gift | 60,000 | $0 | 11/6/2025 | View on chart |
| INSM | ▼ Sell | Gift | 60,000 | $0 | 11/6/2025 | View on chart |
| INSM | ▲ Buy | Grant | 5,058 | — | 5/15/2025 | View on chart |
| INSM | ▲ Buy | Grant | 13,162 | — | 5/13/2024 | View on chart |
| INSM | ▲ Buy | Grant | 13,192 | — | 5/11/2023 | View on chart |
| INSM | ▲ Buy | Grant | 14,645 | — | 5/11/2022 | View on chart |
| INSM | ▲ Buy | Open Market | 10,000 | $302K | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Wolfe Research Downgrades Insmed to Peer Perform Ahead of CHEST 2026
Wolfe Research lowered its rating on Insmed to Peer Perform, joining a wave of recent analyst downgrades. This move comes as the company prepares to present new data for its respiratory portfolio, including the Phase 3 PALM program, at the CHEST 2026 conference. While the stock is currently trading near its 52-week low, other analysts like HC Wainwright remain bullish with a $220 price target.
Wolfe Research Downgrades Insmed to Peer Perform Ahead of CHEST 2026. Wolfe Research lowered its rating on Insmed to Peer Perform, joining a wave of recent analyst downgrades. This move comes as the company prepares to present new data for its respiratory portfolio, including the Phase 3 PALM program, at the CHEST 2026 conference. While the stock is currently trading near its 52-week low, other analysts like HC Wainwright remain bullish with a $220 price target.